London, UK, 20th September 2024: PharmaVentures is pleased to announce the appointment of Angela Acosta as the new Director of Pricing and Market Access. Angela joins the team to enhance PharmaVentures’ growing capabilities in providing strategic support for clients looking to bring their products successfully to market.  

Angela brings over a decade of experience in the pharmaceutical industry, specialising in Pricing and Market Access. With her background as a qualified pharmacist, she has worked across both hospital and community settings in the UK before transitioning to her current focus in Market Access.  

Throughout her career, she has played a pivotal role in shaping market strategies, developing tailored messaging for payers and key opinion leaders (KOLs), and delivering innovative solutions to clients. Her expertise spans global markets, including the US, Canada, the EU5, and the GCC, where she has guided big pharma and small-to-medium biotech companies in preparing for commercial success.  

Angela’s experience includes preparing submissions to the Spanish REvalMed for the evaluation of several central nervous system (CNS) therapies. This work involved the creation of detailed submission dossiers and the adaptation of global budget impact and cost-effectiveness models.  

Her wealth of experience and deep understanding of market dynamics will further strengthen PharmaVentures’ ability to provide world-class Pricing and Market Access support to its global clients.

Dr Fintan Walton, CEO of PharmaVentures, said, “ I am delighted to have Angela on board. She is the perfect person to help us to continue to grow our pricing and market practice. With Angela, we are strengthening our capabilities in this area that is so important to dealmaking and strategic decision making in drug development. Welcome Angela.”

– Ends –

For further information, please contact: 

Ralph Hughes 

Senior Vice President, PharmaVentures, Ltd. 
ralph@pharmaventures.com 

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide. 

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest. 

PharmaVentures’ services include:

• M&A (divestments, mergers, acquisitions, and strategic transactions)
• Licensing (in and out licensing)
• Fundraising Support
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuations (licensing, M&A, and fundraising)
• Pricing and Market Access 

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit https://www.pharmaventures.com

London, UK, 8th August 2024: PharmaVentures is pleased to announce the appointment of Soren Demin as Managing Director and Head of M&A.

Soren’s successful industry and investment banking career, combined with his advisory and medical background, is crucial for understanding clients’ needs and providing optimized solutions. Before this role, Soren served as Chief Business Officer at the Private Equity-backed Essential Pharma. He also held the position of Commercial Director at the UK government’s biological manufacturing unit, Porton BioPharma, where he established new strategic collaborations, directed product development and manufacturing. Previously, Soren was part of Mitsubishi Tanabe Pharma Corporation and the Piramal Group.

Soren embarked on his M&A career with Goldman Sachs, focusing on cross-border deal origination across the US, MENA, Europe, and Asia, before which he studied for a Bachelor of Medicine at the University of Sheffield and a PhD in Biotechnology from the University of Cambridge.”

“I am excited to be joining the PharmaVentures team at this exciting time,” said Soren Demin “So far in 2024 healthcare mergers and acquisitions have surged, with 29 transactions recorded in Q1 alone. The biopharma sector continues to be the main driver representing ~45% of deal volume, with a focus in oncology and inflammation/immunology. Yet despite the challenges such as rising inflation, interest rates, and labour costs, I still anticipate an ongoing global growth and a move to sustainability, through consolidation will drive the Q3/Q4 M&A landscape. Working at PharmaVentures will enable me to help unlock and deliver this added value for our clients”

Dr Fintan Walton, Founder and CEO of PharmaVentures, said, “We are delighted to welcome Soren to PharmaVentures. He has significant experience in all areas of healthcare transactions including Strategy, M&A, Licensing, and fund raising.”

If you would like to learn more about how Soren and PharmaVentures can help your organisation, contact him at soren@pharmaventures.com

– Ends –

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances.

For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning.

PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

• M&A (divestments, mergers, acquisitions, and strategic transactions)
• Licensing (in and out licensing)
• Fundraising Support
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuations (licensing, M&A, and fundraising)
• Pricing and Market Access

PharmaVentures is based in London, UK, and employs over 30 professionals and has associates in Europe and Asia-Pacific.

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit https://www.pharmaventures.com

Follow us on LinkedIn: https://www.linkedin.com/company/pharmaventures/